{"id":25392,"date":"2024-04-03T14:51:12","date_gmt":"2024-04-03T14:51:12","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=25392"},"modified":"2025-12-01T14:57:10","modified_gmt":"2025-12-01T13:57:10","slug":"crispr-cas13-2","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/en\/crispr-cas13-2\/","title":{"rendered":"CRISPR-Cas13"},"content":{"rendered":"

A Revolutionary Technology and its Potential in MECP2 Duplication Syndrome <\/strong><\/p>\n\n

The world of genetic engineering has been revolutionized by the advent of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Among the various types of CRISPR systems, CRISPR-Cas13 stands out due to its unique ability to target RNA, unlike other systems that target permanent DNA genome editing. This article will explore the CRISPR-Cas13 RNA-editing technology and its potential application in treating MECP2 duplication syndrome.<\/p>\n\n

CRISPR-Cas13: A Brief Overview<\/strong><\/p>\n\n

CRISPR-Cas13 is a part of the CRISPR system, a revolutionary tool that has transformed the field of genetic engineering. The CRISPR-Cas13 system is unique because it targets RNA molecules, the intermediaries between DNA and proteins. This allows for a more dynamic and reversible approach to genetic modification, as changes made to RNA do not permanently alter the genome.<\/p>\n\n

The Cas13 protein is an RNA-guided endonuclease that cleaves RNA molecules. It can be programmed with a guide RNA to target and cut any RNA sequence, making it a versatile tool for genetic research and potential therapeutic applications.<\/p>\n\n

The Role of AAV in Administering CRISPR-Cas13<\/strong><\/p>\n\n

In the context of MECP2 Duplication Syndrome, an essential component of the CRISPR-Cas13 system is the vector used for its delivery \u2013 the adeno-associated virus (AAV). AAVs are popular vectors in gene therapy due to their ability to deliver genes to cells with minimal immune response. In the case of CRISPR-Cas13, the AAV vector is used to deliver the Cas13 protein and its guide RNA into cells. This allows the system to reach the targeted RNA molecules and perform its function of cleaving them.<\/p>\n\n

Administration of the Drug<\/strong><\/p>\n\n

For increased bioavailability, the drug is administered directly to the brain. This method ensures that a higher concentration of the drug reaches the target site, increasing its effectiveness.<\/p>\n\n

CRISPR-Cas13 in MECP2 gene duplication syndrome<\/strong><\/p>\n\n

The potential of CRISPR-Cas13 in treating MECP2 duplication syndrome lies in its ability to target and degrade the extra MECP2 mRNA produced due to gene duplication. By reducing the levels of MeCP2 protein, it could potentially alleviate the symptoms of the syndrome.<\/p>\n\n

Conclusion<\/strong><\/p>\n\n

CRISPR-Cas13 represents a promising tool for the treatment of genetic disorders such as duplication syndrome. <\/em>of the MECP2 gene. By targeting the root cause of the disorder at the RNA level, it offers a potential therapeutic strategy that could improve patients' lives. Beyond MECP2 duplication syndrome, the potential applications of CRISPR-Cas13 are vast, including the treatment of other neurological disorders such as Alzheimer's disease, Angelman's syndrome*, etc. <\/p>\n\n

*Jinhui Li, Hui Yang. A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice. Molecular Therapy. 2023 Jul 5; 31 (7): 2286-2295.<\/em><\/p>","protected":false},"excerpt":{"rendered":"

Une technologie r\u00e9volutionnaire \u00e0 haut potentiel dans le syndrome de duplication du g\u00e8ne MECP2 Le monde du g\u00e9nie g\u00e9n\u00e9tique a \u00e9t\u00e9 r\u00e9volutionn\u00e9 par l’av\u00e8nement de la technologie CRISPR. Parmi les […]<\/p>","protected":false},"author":1,"featured_media":4720,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-25392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"\nCRISPR-Cas13 - DupMECP2<\/title>\n<meta name=\"description\" content=\"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l'ARN messager, contrairement \u00e0 d'autres syst\u00e8mes qui ciblent l'ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/en\/crispr-cas13-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR-Cas13 - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l'ARN messager, contrairement \u00e0 d'autres syst\u00e8mes qui ciblent l'ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/en\/crispr-cas13-2\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-03T14:51:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-01T13:57:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1637\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"CRISPR-Cas13\",\"datePublished\":\"2024-04-03T14:51:12+00:00\",\"dateModified\":\"2025-12-01T13:57:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\"},\"wordCount\":531,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\",\"url\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\",\"name\":\"CRISPR-Cas13 - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"datePublished\":\"2024-04-03T14:51:12+00:00\",\"dateModified\":\"2025-12-01T13:57:10+00:00\",\"description\":\"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l'ARN messager, contrairement \u00e0 d'autres syst\u00e8mes qui ciblent l'ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"width\":2560,\"height\":1637},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9\",\"item\":\"https:\/\/dupmecp2.eu\/category\/actualite\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CRISPR-Cas13\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/en\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRISPR-Cas13 - DupMECP2","description":"Among the different types of CRISPR systems, CRISPR-Cas13 stands out for its unique ability to target messenger RNA, unlike other systems that target DNA. This article explores CRISPR-Cas13 technology and its potential application in the treatment of MECP2 gene duplication syndrome.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/en\/crispr-cas13-2\/","og_locale":"en_GB","og_type":"article","og_title":"CRISPR-Cas13 - DupMECP2","og_description":"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l'ARN messager, contrairement \u00e0 d'autres syst\u00e8mes qui ciblent l'ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.","og_url":"https:\/\/dupmecp2.eu\/en\/crispr-cas13-2\/","og_site_name":"DupMECP2","article_published_time":"2024-04-03T14:51:12+00:00","article_modified_time":"2025-12-01T13:57:10+00:00","og_image":[{"width":2560,"height":1637,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Caroline","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"CRISPR-Cas13","datePublished":"2024-04-03T14:51:12+00:00","dateModified":"2025-12-01T13:57:10+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/"},"wordCount":531,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/","url":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/","name":"CRISPR-Cas13 - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","datePublished":"2024-04-03T14:51:12+00:00","dateModified":"2025-12-01T13:57:10+00:00","description":"Among the different types of CRISPR systems, CRISPR-Cas13 stands out for its unique ability to target messenger RNA, unlike other systems that target DNA. This article explores CRISPR-Cas13 technology and its potential application in the treatment of MECP2 gene duplication syndrome.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/crispr-cas13-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","width":2560,"height":1637},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9","item":"https:\/\/dupmecp2.eu\/category\/actualite\/"},{"@type":"ListItem","position":3,"name":"CRISPR-Cas13"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"EU","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/en\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/25392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/comments?post=25392"}],"version-history":[{"count":1,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/25392\/revisions"}],"predecessor-version":[{"id":33396,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/25392\/revisions\/33396"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/media\/4720"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/media?parent=25392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/categories?post=25392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/tags?post=25392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}